SIDE-BY-SIDE EVIDENCE
Compare evidence.
Keep the context.
Select 2–3 profiles from the English Library. Class and grade describe evidence and regulatory context, not comparative effectiveness or suitability for an individual.
Choose profilesSIDE-BY-SIDE EVIDENCE VIEW
Compare selected profiles
| Molecule |  Clenbuterol | Salbutamol / Albuterol | Liothyronine sodium / T3 |
|---|---|---|---|
| Research Topic | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology | Clinical / Endocrine Pharmacology |
| Pharmacology | Long-acting beta-2 adrenergic agonist not FDA-approved for human use | Short-acting beta-2 adrenergic agonist medicine | Prescription thyroid hormone (synthetic T3) |
| PrimeCore Class | Class BInvestigational | Class AApproved in a bounded context | Class AApproved in a bounded context |
| Evidence Grade | Grade EPreclinical evidence | Grade AStrong regulatory + clinical evidence | Grade AStrong regulatory + clinical evidence |
| Evidence boundary | Clenbuterol is classified here as Long-acting beta-2 adrenergic agonist not FDA-approved for human use. Human misuse reports and veterinary/regulatory records are more relevant than performance claims; no FDA-approved human product exists. Not FDA-approved for human use; prohibited by WADA under beta-2 agonists at all times except narrowly specified permitted inhaled medicines that do not include clenbuterol. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Salbutamol / Albuterol is classified here as Short-acting beta-2 adrenergic agonist medicine. Strong clinical evidence applies to authorised inhaled products and respiratory indications, not catalogue tablets for weight loss or performance. FDA-authorised respiratory products exist; WADA permits only specified inhaled salbutamol conditions and thresholds, while other routes/use are prohibited. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. | Liothyronine sodium / T3 is classified here as Prescription thyroid hormone (synthetic T3). Current labels support defined thyroid indications and carry a boxed warning against use for obesity or weight loss. FDA-authorised prescription labels exist for defined thyroid indications; WADA status and TUE requirements must be checked for an athlete's exact context. A catalogue name does not establish identity, formulation, quality or authorisation, and this page provides no dosage, mixing, injection or purchasing instructions. |
| Unknowns | Insufficient data in the current dataset | Insufficient data in the current dataset | Insufficient data in the current dataset |
| Limitations |
|
|
|
| Sources | |||
| Read more | Read English overview | Read English overview | Read English overview |
This table does not compare doses, cross-trial outcomes or individual suitability. Missing information does not establish an absence of risk.
Choose another comparisonContinue reading
Missing fields mean information is unavailable in the current structured dataset, not that a molecule has no risks or uncertainties. English translations retain the original evidence boundaries. Where translation is not yet verified, the original Thai excerpts remain available under an explicit label. Sources retain their original language.
10 questions before drawing conclusions